Pfizer Gets Bitten
Tweet
Share
E-mailGet Alerts PFE Hot Sheet
Price: $28.67 +0.92%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 6.9%
EPS Growth %: -12.6%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 6.9%
EPS Growth %: -12.6%
Join SI Premium – FREE
From 247WallSt
Life does not get any easier for Pfizer (NYSE: PFE). Forget generics. Now other drug firms are ganging up on them. Merck (NYSE: MRK) and Schering-Plough (NYSE: SGP) are going to offer drug that combines their cholestoral drug with Pfizer blockbuster Lipitor. Its patent expires in three years.
Pfizer has defied gravity this year. Its stock trades at $25.66. In July, it was down to $22.28. The company has cut considerable staff. But, unless it has some rabbits in the pipeline hat, life is about to get very rough.
For more market insight go to http://www.247wallst.com/
Life does not get any easier for Pfizer (NYSE: PFE). Forget generics. Now other drug firms are ganging up on them. Merck (NYSE: MRK) and Schering-Plough (NYSE: SGP) are going to offer drug that combines their cholestoral drug with Pfizer blockbuster Lipitor. Its patent expires in three years.
Pfizer has defied gravity this year. Its stock trades at $25.66. In July, it was down to $22.28. The company has cut considerable staff. But, unless it has some rabbits in the pipeline hat, life is about to get very rough.
For more market insight go to http://www.247wallst.com/
You May Also Be Interested In
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- B. Riley’s Top Biotech Picks Ahead of 3Q26 Earnings Season
- Pfizer Invites Public to View and Listen to Webcast of November 3 Conference Call with Analysts
Create E-mail Alert Related Categories
ContributorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
